Arrowhead Pharmaceuticals, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000BRVKH0
ARWR
Arrowhead Pharmaceuticals, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Arrowhead Pharmaceuticals, Inc.
ISIN
US04280A1007
TICKER
ARWR
MIC
XNAS
REUTERS
ARWR.OQ
BLOOMBERG
ARWR US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 05.11.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations p...
Arrowhead Pharmaceuticals
Mo., 04.11.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe H...
Arrowhead Pharmaceuticals
Fr., 01.11.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today, on FCS Awareness Day, announced the launch of a new disease awareness campaign, 'We'll Get There Soon,' to bring hope to the rare disease community affected by Familial Chylomicronemia Syndrome (FCS). The campaign seeks to raise awareness about FCS, a severe and rare condition marked by persist...
Arrowhead Pharmaceuticals
Mo., 14.10.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 66,...
Arrowhead Pharmaceuticals
Mo., 23.09.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end ...
Arrowhead Pharmaceuticals
Di., 10.09.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease characterized by ...
Arrowhead Pharmaceuticals
Mo., 02.09.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully met its primary endpoint and all multiplicity-c...
Arrowhead Pharmaceuticals
Mi., 21.08.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September 2, 2024. The company will also host a virtual analyst and investor event on Septe...
Arrowhead Pharmaceuticals
Mi., 14.08.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduc...
Arrowhead Pharmaceuticals
Do., 08.08.2024
Arrowhead Pharmaceuticals
US04280A1007
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results.
“Arrowhead had a very productive quarter with several high-profile presentations at medical and scientific ...
Arrowhead Pharmaceuticals
Informationen zu Product Placements
